Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy.
Antitumor activities have been described in selol, a hydrophobic mixture of molecules containing selenium in their structure, and also in maghemite magnetic nanoparticles (MNPs). Both selol and MNPs were co-encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanocapsules for therapeutic purposes. The PLGA-nanocapsules loaded with MNPs and selol were labeled MSE-NC and characterized by transmission and scanning electron microscopy, electrophoretic mobility, photon correlation spectroscopy, presenting a monodisperse profile, and positive charge. The antitumor effect of MSE-NC was evaluated using normal (MCF-10A) and neoplastic (4T1 and MCF-7) breast cell lines. Nanocapsules containing only MNPs or selol were used as control. MTT assay showed that the cytotoxicity induced by MSE-NC was dose and time dependent. Normal cells were less affected than tumor cells. Cell death occurred mainly by apoptosis. Further exposure of MSE-NC treated neoplastic breast cells to an alternating magnetic field increased the antitumor effect of MSE-NC. It was concluded that selol-loaded magnetic PLGA-nanocapsules (MSE-NC) represent an effective magnetic material platform to promote magnetohyperthermia and thus a potential system for antitumor therapy.
Instituto de Ciências Biológicas, Universidade de Brasília, Brasília DF, Brazil.
Luciana L C
LL
Estevanato
Jaqueline R
JR
Da Silva
André M
AM
Falqueiro
Ewa
E
Mosiniewicz-Szablewska
Piotr
P
Suchocki
Antônio C
AC
Tedesco
Paulo C
PC
Morais
Zulmira G M
ZG
Lacava
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D005260:Female; D006979:Hyperthermia, Induced / Q000379:methods*; D058185:Magnetite Nanoparticles / Q000737:chemistry* / Q000627:therapeutic use* / Q000648:ultrastructure; D051379:Mice; D053769:Nanocapsules / Q000737:chemistry* / Q000627:therapeutic use* / Q000648:ultrastructure; D018036:Selenium Compounds / Q000008:administration & dosage*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D058185:Magnetite Nanoparticles; D053769:Nanocapsules; D018036:Selenium Compounds; C105370:selol